Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene hunt: why does sunitinib work differently in kidney cancer patients?

NCT ID NCT02404584

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study enrolled 43 people with kidney cancer who were starting sunitinib (Sutent). Researchers measured the drug's level in the blood and checked for genetic differences that might affect how the body processes it. The goal was to understand why sunitinib levels vary from person to person, which could eventually help tailor dosing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sunitinib (Sutent)
What this could lead to
If successful, this could help doctors personalize sunitinib dosing for kidney cancer patients to improve effectiveness.
What could go wrong
This is a small, observational study that only measures drug levels and genes. It does not test a new treatment or change in care, so direct patient benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

43 people

The number who actually took part.

Started

Dec 2015

Finished

May 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consisted of patients with renal cell carcinoma treated with sunitinib (Sutent).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient was correctly informed concerning the implementation of the study, its objectives, constraints and patient rights * The patient must have given his/her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient has kidney cancer and should begin treatment with sunitinib (Sutent) at the time of inclusion Exclusion Criteria: * The patient started treatment with sunitinib (Sutent) before inclusion * The patient is participating in another interventional study * The patient has participated in another interventional study within the last month * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant, parturient, or breastfeeding * The patient has a contraindication (or an incompatible drug combination) for a treatment used in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

kidney cancer kidney neoplasm renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney neoplasms

Contacts and locations

Locations

  • CHRU de Montpellier - Hôpital Saint-Eloi

    Montpellier, 34295, France

  • CHRU de Nîmes - Hôpital Universitaire Carémeau

    Nîmes, 30029, France

  • Institut de Cancérologie du Gard (ICG)

    Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.